These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 11323013

  • 1. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 2. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 01; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 3. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
    Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK.
    J Thromb Haemost; 2009 Jun 01; 7(6):983-91. PubMed ID: 19548907
    [Abstract] [Full Text] [Related]

  • 4. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M, Bertram U, Peter K, Bode C, Ruef J.
    J Cardiovasc Pharmacol; 2003 Apr 01; 41(4):586-92. PubMed ID: 12658060
    [Abstract] [Full Text] [Related]

  • 5. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R.
    J Thromb Thrombolysis; 2001 Oct 01; 12(2):129-39. PubMed ID: 11729364
    [Abstract] [Full Text] [Related]

  • 6. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 01; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

  • 7. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 8. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 15; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 9. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 10. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE, Furman RR, Lands LT, Moodie GD, Jennings LK.
    J Thromb Thrombolysis; 2013 Jul 04; 36(1):31-41. PubMed ID: 23073747
    [Abstract] [Full Text] [Related]

  • 13. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr 04; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

  • 14. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 15. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Sep 01; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
    Haga JH, Jennings LK, Slack SM.
    Ann Biomed Eng; 2002 Sep 01; 30(10):1262-72. PubMed ID: 12540202
    [Abstract] [Full Text] [Related]

  • 17. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN, Hogan DF, Sederquist KA, Durham JA.
    Am J Vet Res; 2014 Mar 01; 75(3):309-12. PubMed ID: 24564318
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.
    J Thromb Thrombolysis; 1999 Jun 01; 7(3):265-76. PubMed ID: 10375388
    [Abstract] [Full Text] [Related]

  • 19. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 01; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 20. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schömig A, Gawaz M.
    J Am Coll Cardiol; 2001 Apr 01; 37(5):1323-8. PubMed ID: 11300442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.